Cargando…
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
BACKGROUND: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. OBJECTIVE: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149255/ https://www.ncbi.nlm.nih.gov/pubmed/35651755 http://dx.doi.org/10.3389/fcimb.2022.906563 |
_version_ | 1784717169699848192 |
---|---|
author | Quindós, Guillermo Miranda-Cadena, Katherine San-Millán, Rosario Borroto-Esoda, Katyna Cantón, Emilia Linares-Sicilia, María José Hamprecht, Axel Montesinos, Isabel Tortorano, Anna Maria Prigitano, Anna Vidal-García, Matxalen Marcos-Arias, Cristina Guridi, Andrea Sanchez-Reus, Ferran Machuca-Bárcena, Jesús Rodríguez-Iglesias, Manuel Antonio Martín-Mazuelos, Estrella Castro-Méndez, Carmen López-Soria, Leyre Ruiz-Gaitán, Alba Fernandez-Rivero, Marcelo Lorenzo, Damaris Capilla, Javier Rezusta, Antonio Pemán, Javier Guarro, Josep Pereira, Joana Pais, Célia Romeo, Orazio Ezpeleta, Guillermo Jauregizar, Nerea Angulo, David Eraso, Elena |
author_facet | Quindós, Guillermo Miranda-Cadena, Katherine San-Millán, Rosario Borroto-Esoda, Katyna Cantón, Emilia Linares-Sicilia, María José Hamprecht, Axel Montesinos, Isabel Tortorano, Anna Maria Prigitano, Anna Vidal-García, Matxalen Marcos-Arias, Cristina Guridi, Andrea Sanchez-Reus, Ferran Machuca-Bárcena, Jesús Rodríguez-Iglesias, Manuel Antonio Martín-Mazuelos, Estrella Castro-Méndez, Carmen López-Soria, Leyre Ruiz-Gaitán, Alba Fernandez-Rivero, Marcelo Lorenzo, Damaris Capilla, Javier Rezusta, Antonio Pemán, Javier Guarro, Josep Pereira, Joana Pais, Célia Romeo, Orazio Ezpeleta, Guillermo Jauregizar, Nerea Angulo, David Eraso, Elena |
author_sort | Quindós, Guillermo |
collection | PubMed |
description | BACKGROUND: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. OBJECTIVE: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. METHODS: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. RESULTS: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. CONCLUSION: Ibrexafungerp showed a potent in vitro activity against Candida. |
format | Online Article Text |
id | pubmed-9149255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91492552022-05-31 In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study Quindós, Guillermo Miranda-Cadena, Katherine San-Millán, Rosario Borroto-Esoda, Katyna Cantón, Emilia Linares-Sicilia, María José Hamprecht, Axel Montesinos, Isabel Tortorano, Anna Maria Prigitano, Anna Vidal-García, Matxalen Marcos-Arias, Cristina Guridi, Andrea Sanchez-Reus, Ferran Machuca-Bárcena, Jesús Rodríguez-Iglesias, Manuel Antonio Martín-Mazuelos, Estrella Castro-Méndez, Carmen López-Soria, Leyre Ruiz-Gaitán, Alba Fernandez-Rivero, Marcelo Lorenzo, Damaris Capilla, Javier Rezusta, Antonio Pemán, Javier Guarro, Josep Pereira, Joana Pais, Célia Romeo, Orazio Ezpeleta, Guillermo Jauregizar, Nerea Angulo, David Eraso, Elena Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. OBJECTIVE: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. METHODS: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. RESULTS: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. CONCLUSION: Ibrexafungerp showed a potent in vitro activity against Candida. Frontiers Media S.A. 2022-05-16 /pmc/articles/PMC9149255/ /pubmed/35651755 http://dx.doi.org/10.3389/fcimb.2022.906563 Text en Copyright © 2022 Quindós, Miranda-Cadena, San-Millán, Borroto-Esoda, Cantón, Linares-Sicilia, Hamprecht, Montesinos, Tortorano, Prigitano, Vidal-García, Marcos-Arias, Guridi, Sanchez-Reus, Machuca-Bárcena, Rodríguez-Iglesias, Martín-Mazuelos, Castro-Méndez, López-Soria, Ruiz-Gaitán, Fernandez-Rivero, Lorenzo, Capilla, Rezusta, Pemán, Guarro, Pereira, Pais, Romeo, Ezpeleta, Jauregizar, Angulo and Eraso https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Quindós, Guillermo Miranda-Cadena, Katherine San-Millán, Rosario Borroto-Esoda, Katyna Cantón, Emilia Linares-Sicilia, María José Hamprecht, Axel Montesinos, Isabel Tortorano, Anna Maria Prigitano, Anna Vidal-García, Matxalen Marcos-Arias, Cristina Guridi, Andrea Sanchez-Reus, Ferran Machuca-Bárcena, Jesús Rodríguez-Iglesias, Manuel Antonio Martín-Mazuelos, Estrella Castro-Méndez, Carmen López-Soria, Leyre Ruiz-Gaitán, Alba Fernandez-Rivero, Marcelo Lorenzo, Damaris Capilla, Javier Rezusta, Antonio Pemán, Javier Guarro, Josep Pereira, Joana Pais, Célia Romeo, Orazio Ezpeleta, Guillermo Jauregizar, Nerea Angulo, David Eraso, Elena In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study |
title |
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study |
title_full |
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study |
title_fullStr |
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study |
title_full_unstemmed |
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study |
title_short |
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study |
title_sort | in vitro antifungal activity of ibrexafungerp (scy-078) against contemporary blood isolates from medically relevant species of candida: a european study |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149255/ https://www.ncbi.nlm.nih.gov/pubmed/35651755 http://dx.doi.org/10.3389/fcimb.2022.906563 |
work_keys_str_mv | AT quindosguillermo invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT mirandacadenakatherine invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT sanmillanrosario invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT borrotoesodakatyna invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT cantonemilia invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT linaressiciliamariajose invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT hamprechtaxel invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT montesinosisabel invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT tortoranoannamaria invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT prigitanoanna invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT vidalgarciamatxalen invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT marcosariascristina invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT guridiandrea invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT sanchezreusferran invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT machucabarcenajesus invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT rodrigueziglesiasmanuelantonio invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT martinmazuelosestrella invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT castromendezcarmen invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT lopezsorialeyre invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT ruizgaitanalba invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT fernandezriveromarcelo invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT lorenzodamaris invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT capillajavier invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT rezustaantonio invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT pemanjavier invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT guarrojosep invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT pereirajoana invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT paiscelia invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT romeoorazio invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT ezpeletaguillermo invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT jauregizarnerea invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT angulodavid invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy AT erasoelena invitroantifungalactivityofibrexafungerpscy078againstcontemporarybloodisolatesfrommedicallyrelevantspeciesofcandidaaeuropeanstudy |